Ho AD - Search Results

1

Addition of rituximab to CHOP-like chemotherapy in first line treatment of primary mediastinal B-cell lymphoma.

Lisenko K, Dingeldein G, Cremer M, Kriegsmann M, Ho AD, Rieger M, Witzens-Harig M. Lisenko K, et al. Among authors: ho ad. BMC Cancer. 2017 May 22;17(1):359. doi: 10.1186/s12885-017-3332-3. BMC Cancer. 2017. PMID: 28532396 Free PMC article.

2

Etoposide in acute leukemia. Past experience and future perspectives.

Ho AD, Brado B, Haas R, Hunstein W. Ho AD, et al. Cancer. 1991 Jan 1;67(1 Suppl):281-4. doi: 10.1002/1097-0142(19910101)67:1+<281::aid-cncr2820671312>3.0.co;2-h. Cancer. 1991. PMID: 1984828 Review.

3

Mitoxantrone/high-dose Ara-C and recombinant human GM-CSF in the treatment of refractory non-Hodgkin's lymphoma. A pilot study.

Ho AD, Del Valle F, Engelhard M, Hiddemann W, Rückle H, Schlimok G, Haas R, Thiel E, Andreesen R, Fiedler W, et al. Ho AD, et al. Cancer. 1990 Aug 1;66(3):423-30. doi: 10.1002/1097-0142(19900801)66:3<423::aid-cncr2820660304>3.0.co;2-v. Cancer. 1990. PMID: 2194641 Clinical Trial.

4

Mitoxantrone and high-dose cytarabine as salvage therapy for refractory non-Hodgkin's lymphoma.

Ho AD, del Valle F, Rückle H, Schwammborn J, Schlimok G, Hiddemann W, Meusers P, Thiel E, Dörken B, Hunstein W. Ho AD, et al. Cancer. 1989 Oct 1;64(7):1388-92. doi: 10.1002/1097-0142(19891001)64:7<1388::aid-cncr2820640703>3.0.co;2-0. Cancer. 1989. PMID: 2776103

5

Tandem high-dose chemotherapy in high-risk primary breast cancer: a multivariate analysis and a matched-pair comparison with standard-dose chemotherapy.

Schneeweiss A, Goerner R, Hensel MA, Lauschner I, Sinn P, Kaul S, Egerer G, Beldermann F, Geberth M, Solomayer E, Grischke EM, Haas R, Ho AD, Bastert G. Schneeweiss A, et al. Among authors: ho ad. Biol Blood Marrow Transplant. 2001;7(6):332-42. doi: 10.1016/s1083-8791(01)80004-5. Biol Blood Marrow Transplant. 2001. PMID: 11464976 Free article.

6

Outpatient treatment of multiple myeloma with a combination of vincristine, Adriamycin and dexamethasone.

Egerer G, Hegenbart U, Salwender H, Haas R, Hahn U, Schmier JW, Ho AD, Goldschmidt H. Egerer G, et al. Among authors: ho ad. Support Care Cancer. 2001 Jul;9(5):380-5. doi: 10.1007/s005200000224. Support Care Cancer. 2001. PMID: 11497393

7

Remarkable response to rituximab in a 72-year-old patient with refractory non-Hodgkin's lymphoma and marrow aplasia.

Egerer G, Sauerland K, Ho AD. Egerer G, et al. Among authors: ho ad. Leuk Lymphoma. 2001 Jul;42(3):551-3. doi: 10.3109/10428190109064616. Leuk Lymphoma. 2001. PMID: 11699424

8

Characteristics associated with long-term progression-free survival following high-dose chemotherapy in metastatic breast cancer and influence of chemotherapy dose.

Schneeweiss A, Hensel M, Sinn P, Khbeis T, Haas R, Bastert G, Ho AD. Schneeweiss A, et al. Among authors: ho ad. Ann Oncol. 2002 May;13(5):679-88. doi: 10.1093/annonc/mdf168. Ann Oncol. 2002. PMID: 12075735 Free article.

9

P53 is the strongest predictor of survival in high-risk primary breast cancer patients undergoing high-dose chemotherapy with autologous blood stem cell support.

Hensel M, Schneeweiss A, Sinn HP, Egerer G, Solomayer E, Haas R, Bastert G, Ho AD. Hensel M, et al. Among authors: ho ad. Int J Cancer. 2002 Jul 20;100(3):290-6. doi: 10.1002/ijc.10478. Int J Cancer. 2002. PMID: 12115543

10

High-dose chemotherapy with autologous peripheral blood stem cell transplantation for bone and soft-tissue sarcomas.

Kasper B, Lehnert T, Bernd L, Mechtersheimer G, Goldschmidt H, Ho AD, Egerer G. Kasper B, et al. Among authors: ho ad. Bone Marrow Transplant. 2004 Jul;34(1):37-41. doi: 10.1038/sj.bmt.1704520. Bone Marrow Transplant. 2004. PMID: 15170176

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

720 results

Search Page

Filters